Journal article
Long-term adjunctive lacosamide treatment in patients with partial-onset seizures
F Rosenow, A Kelemen, E Ben-Menachem, C Mcshea, J Isojarvi, P Doty, S Berkovic, M Kiley, T O'Brien, DC Reutens, WU Seneviratne, MK Robinson, GJ Schapel, ER Somerville, T Babic, Z Poljakovic, V Demarin, S Hajnsek, M Bar, J Buresova Show all
Acta Neurologica Scandinavica | WILEY | Published : 2016
DOI: 10.1111/ane.12451
Open access
Abstract
Objective: To evaluate long-term (up to 5.5 years) safety, seizure reduction, and maintenance of efficacy of the antiepileptic drug (AED) lacosamide as adjunctive treatment in an open-label extension trial (SP774; ClinicalTrials.gov: NCT00515619). Methods: Three hundred and seventy-six adults with partial-onset seizures taking 1-3 AEDs enrolled following completion of a double-blind trial of adjunctive lacosamide. During open-label treatment, dosage of lacosamide (100-800 mg/day) and/or concomitant AEDs could be adjusted to optimize tolerability and seizure control. Results: Kaplan-Meier estimates of patient retention were 74.5% at 12 months, 52.9% at 36 months, and 40.6% at 60 months; media..
View full abstractGrants
Funding Acknowledgements
The authors acknowledge Anthony Daniels, UCB Pharma, Raleigh, NC, USA, and Maria-Luise Esch, UCB Pharma, Monheim am Rhein, Germany, for clinical project management, and Jennifer Hepker, PhD of PMCG, Chicago, IL, USA, and Steve Dobson of Evidence Scientific Solutions, Horsham, UK, for writing support, which was funded by UCB Pharma.